
Uppsala Reports editor
@UMCGlobalSafety
What are the implications for signal detection when new approaches to reporting create greater data streams than have ever been present for older medicinal products?
The successful rollout of the COVID-19 vaccines was supported by a stream of reports of potential adverse drug reactions. This is great for vaccine safety, but what of the ability to detect signals from other drugs?
In the latest episode of Drug Safety Matters, join Federica Santoro and Sara Vidlin, a data scientist at UMC, as they discuss how this imbalance of COVID-19 vaccine reports presents challenges for detecting signals for other drugs through the statistical phenomenon of ‘masking’. Learn how they detect it, how it affects their data analysis, and what researchers can do to ‘unmask’ impacted data to ensure accurate drug reaction surveillance.
This episode is part of the Uppsala Reports long read series, a selection of the most relevant stories from Uppsala Reports magazine in audio format. Read the original article here. Subscribe by visiting the Drug Safety Matters website.
After decades of slow but steady growth, VigiBase has recently entered a new phase of accelerating expansion, driven by a range of converging forces.
Signal detection / 16 September 2021
Ever wondered how safety surveillance differs between vaccines and drugs? Find out in the latest episode of the Drug Safety Matters podcast.
Signal detection / 25 August 2022
UMC experts discuss how real-time vaccine surveillance works during a pandemic and the role of VigiBase in helping to ensure public safety.
Signal detection / 29 June 2021